3337-59-5 Usage
General Description
Methyl 3,5-dichloro-4-hydroxybenzoate is a chemical compound commonly used in the manufacturing of pharmaceuticals, personal care products, and industrial applications. It is a derivative of benzoic acid, and its molecular structure contains two chlorine atoms and a hydroxy group attached to a methyl ester. METHYL 3,5-DICHLORO-4-HYDROXYBENZOATE exhibits antimicrobial properties and is often incorporated into skincare products and topical ointments for its preservative and antiseptic effects. Additionally, its unique chemical properties make it useful in pesticide formulations and as an intermediate in the synthesis of other organic compounds. Overall, methyl 3,5-dichloro-4-hydroxybenzoate is a versatile and valuable chemical with a wide range of applications across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 3337-59-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,3,3 and 7 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 3337-59:
(6*3)+(5*3)+(4*3)+(3*7)+(2*5)+(1*9)=85
85 % 10 = 5
So 3337-59-5 is a valid CAS Registry Number.
InChI:InChI=1/C8H6Cl2O3/c1-13-8(12)4-2-5(9)7(11)6(10)3-4/h2-3,11H,1H3
3337-59-5Relevant articles and documents
CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE
-
Paragraph 0246, (2019/11/11)
The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a β2-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma.
Induction of apoptosis in cancer cells
-
, (2008/06/13)
The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.
